NEW YORK _ Pfizer Inc. and BioNTech will submit data to the Food and Drug Administration in coming weeks supporting a COVID-19 vaccine booster shot. The companies have seen “encouraging data” in the trial of a third dose of their vaccine, they said Thursday. “Initial data from the study demonstrate that a booster dose given
NEW YORK — Pfizer announced on Monday that the vaccine the company jointly developed with BioNTech was 90% effective in preventing COVID-19 infections in ongoing Phase 3 trials. Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings. “The first set of
NEW YORK — Pfizer and BioNTech SE announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government’s Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. Under the agreement, the U.S.
NEW YORK — Pfizer and BioNTech SE announced Tuesday that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.